William Blair analyst Matt Phipps has maintained their bullish stance on XNCR stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Phipps has given his Buy rating due to a combination of factors tied to Xencor’s TL1A franchise and its emerging clinical profile. He views XmAb942 as a differentiated second‑generation TL1A antibody, supported by final Phase I data showing class-consistent safety, a long human half‑life that enables quarterly dosing, and an immunogenicity profile that appears manageable at the intended Phase IIb dose.
Phipps also sees strategic value in Xencor’s broader TL1A platform, including the bispecific XmAb412, against the backdrop of strong external validation from TL1A-focused data at DDW. In his view, the company is well-positioned to capitalize on growing interest in TL1A-targeted therapies for inflammatory bowel disease, and upcoming Phase IIb induction results for XmAb942 represent a meaningful catalyst that can unlock further upside in XNCR.
In another report released today, Barclays also maintained a Buy rating on the stock with a $27.00 price target.